GlioVision: A Multi-Modal MRI Framework for Non-Invasive Glioma Molecular Biomarkers Prediction

Gliomas are aggressive primary brain tumors that necessitate critical molecular biomarker predictions for optimal clinical decision-making. Traditional assessment relies on surgical tumor specimens analysis, which carries procedural risks and sampling bias due to tumor heterogeneity. Existing deep learning methods for non-invasive prediction lack real-time applicability, remain resource-intensive, and are frequently trained on narrowly represented datasets. We present GlioVision, a framework built on the MONAI library to process multimodal data, including glioma MRI and molecular labels, to predict and identify, non-invasively, four major glioma molecular biomarkers: IDH mutation, 1p/19q co-deletion, MGMT methylation, and WHO grade. The core architecture comprises Spatially and Channel-wise Recalibrated 3D DenseNet (SCRU-DenseNet), which utilizes a computational attention gate and an Adaptive Contrast-Specific Processing Stream (ACPS) to tackle multi-site, heterogeneous datasets. We introduced the Confidence-Filtered Predictive Manifold (CFPM) to manage uncertainty by excluding predictions with low confidence. GlioVision is trained and validated on the largest multi-cohort datasets, achieving strong biomarker prediction with AUCs of (IDH 0.94, 1p/19q 0.87, MGMT 0.86, WHO grades 0.92), supporting molecularly defined glioma diagnosis under the WHO 2021 classification guidelines. Finally, we provide a Differential Training Integrity Assessment (DTI-A) to analyze routes of MRI data privacy protections through model obfuscation. Our results advance the codebase, model release, and leakage considerations around MRI data analysis literature.